ERBB3 and breast cancer: The phase 1/2 study U3-1402-J101 study included patients with HER3 + (IHC 2 + or 3 +) heavily pretreated metastatic BC: 113 with luminal, 53 with TNBC and 14 with HER2-positive BC.